首页> 外文期刊>Vaccine >A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination
【24h】

A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination

机译:基于从Omp31到BLS N末端插入27个氨基酸的重组亚单位疫苗,与Rev.1疫苗相比,诱导的针对牛双歧杆菌的保护程度相似

获取原文
获取原文并翻译 | 示例
           

摘要

The development of an effective subunit vaccine against brucellosis is a research area of intense interest. The enzyme lumazine synthase from Brucella spp. (BLS) is highly immunogenic, presumably due to its decameric arrangement and remarkable stability. In this work we decided to develop a chimera with the scaffold protein BLS decorated with 10 copies of a known protective epitope derived from an outer membrane protein of 31kDa (Omp31) from Brucella spp. Vaccination of BALB/c mice with the chimera as a recombinant protein (rBLSOmp31) provided the best protection level against Brucella ovis, which was higher than the given by the co-delivery of both recombinant proteins (rBLS+rOmp31) and similar than the control vaccine Brucella melitensis strain Rev.1. Moreover rBLSOmp31 induced protection against Brucella melitensis but to a lesser degree than Rev.1. The chimera induced a strong humoral response against the inserted peptide. It also induced peptide- and BLS-specific T helper 1 and cytotoxic T responses. In conclusion, our results indicate that BLSOmp31 could be a useful candidate for the development of subunit vaccines against brucellosis since it elicits humoral, T helper and cytotoxic immune responses and protection against smooth and rough species of Brucella.
机译:对抗布鲁氏菌病的有效亚单位疫苗的开发是引起人们极大兴趣的研究领域。来自布鲁氏菌属的酶lumazine合酶。 (BLS)具有高度免疫原性,可能是由于其十聚体排列和出色的稳定性。在这项工作中,我们决定开发一种由支架蛋白BLS组成的嵌合体,该支架蛋白上装饰有10个拷贝的已知保护性表位,该表位来自布鲁氏菌属的31kDa(Omp31)外膜蛋白。用嵌合体作为重组蛋白(rBLSOmp31)接种BALB / c小鼠可提供最佳的针对布鲁氏菌的保护水平,这高于两种重组蛋白(rBLS + rOmp31)共同递送所提供的保护水平,并且与对照相似疫苗布鲁氏菌菌株Rev.1。而且,rBLSOmp31诱导了针对布鲁氏菌的保护,但是程度低于Rev.1。嵌合体对插入的肽产生强烈的体液反应。它还诱导了肽和BLS特异性T辅助物1和细胞毒性T反应。总之,我们的结果表明,BLSOmp31可能引发抗布鲁氏菌病亚单位疫苗的开发,因为它引起体液,T辅助和细胞毒性免疫反应,并能抵抗布鲁氏菌的平滑和粗糙物种。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号